NewGenIvf Group Ltd
NIVFAnalytical Summary
NewGenIvf Group Ltd shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
5-Year Financial Trajectory
AnnualBullish Indicators
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ | FY 2021 Dec 31, 2021 20-F ↗ |
|---|---|---|---|---|---|
| Revenue Growth YoY (%) |
-13.0%
Weak
↓
Weak
Declining
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-263%)
|
5.8%
Fair
↓
Fair
Declining
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-28%)
|
-13.6%
Weak
Weak
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-270%)
|
44.3%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+454%)
|
— |
| EPS Growth YoY (%) | N/M | N/M |
341.2%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) | N/M | N/M |
-71.6%
Weak
Weak
Year-over-year change in net income |
N/M | — |
| FCF Growth YoY (%) | — | — | — |
11.0%
Fair
Fair
Year-over-year change in free cash flow |
— |
| Revenue CAGR 3Y (%) |
-7.4%
Weak
Weak
Compound annual revenue growth over 3 years |
9.7%
Fair
Fair
Compound annual revenue growth over 3 years |
— | — | — |
| EPS CAGR 3Y (%) |
545.1%
Excellent
Excellent
Compound annual EPS growth over 3 years |
— | — | — | — |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ | FY 2021 Dec 31, 2021 20-F ↗ |
|---|---|---|---|---|---|
| Operating Margin (%) (%) |
-226.9%
Weak
↓
Weak
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1613%)
|
-21.4%
Weak
↓
Weak
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-242%)
|
0.8%
Weak
↓
Weak
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-95%)
|
6.7%
Caution
Caution
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-55%)
|
4.8%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-68%)
|
| Effective Tax Rate (%) (%) | — |
50.7%
Weak
↓
Weak
Declining
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
60.5%
Weak
Weak
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
188.7%
Weak
Weak
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
| Profit Margin (%) (%) | — |
-9.7%
Weak
↓
Weak
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-180%)
|
2.5%
Weak
↓
Weak
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-79%)
|
7.7%
Caution
Caution
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-36%)
|
-0.0%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-100%)
|
| FCF Margin (%) (%) |
-234.0%
Weak
↓
Weak
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-153.1%
Weak
↓
Weak
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-35.7%
Weak
↓
Weak
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
27.2%
Excellent
Excellent
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
34.4%
Excellent
Excellent
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
| FCF / Net Income (x) |
-1.12x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
15.85x
Excellent
↑
Excellent
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
-14.10x
Weak
↑
Weak
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
3.52x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
-2657.46x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ | FY 2021 Dec 31, 2021 20-F ↗ |
|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-31.8%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
54.6%
Excellent
↑
Excellent
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
0.9%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
28.0%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-32.8%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-32.4%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
0.9%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
13.7%
Good
Good
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
37.1%
Excellent
↓
Excellent
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+147%)
|
50.0%
Excellent
↑
Excellent
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+234%)
|
3.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-77%)
|
81.5%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+443%)
|
— |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ | FY 2021 Dec 31, 2021 20-F ↗ |
|---|---|---|---|---|---|
| Interest Coverage (x) |
-17.40x
Weak
↓
Weak
Declining
Operating income divided by interest expense
Optimal:
> 5x
|
-1.52x
Weak
↓
Weak
Declining
Operating income divided by interest expense
Optimal:
> 5x
|
0.91x
Weak
↓
Weak
Declining
Operating income divided by interest expense
Optimal:
> 5x
|
7.19x
Good
Good
Operating income divided by interest expense
Optimal:
> 5x
|
3.03x
Fair
Fair
Operating income divided by interest expense
Optimal:
> 5x
|
| Net Debt (USD) | $-758.62K | $-457.74K | $-54.10K | $-27.56K | — |
| Metric | FY 2025 Dec 31, 2025 20-F ↗ | FY 2024 Dec 31, 2024 20-F ↗ | FY 2023 Dec 31, 2023 20-F ↗ | FY 2022 Dec 31, 2022 20-F ↗ | FY 2021 Dec 31, 2021 20-F ↗ |
|---|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $4.73M | $5.43M | $5.14M | $5.94M | $4.12M |
| Depreciation Expense (USD) | $188.11K | $19.50K | $31.17K | $100.53K | $166.71K |
| Net Income, GAAP (USD) | $9.88M | $-524.64K | $130.19K | $458.67K | $-533.00 |
| Operating Cash Flow (USD) | $-10.93M | $-8.26M | $-1.77M | $1.71M | $1.43M |
Secondary lens
Benchmark Lens
Compare NIVF against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare NIVF against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for NIVF
Return on Common Equity (%) is in the top quartile
Operating Margin (%) is in the bottom quartile
Percentile Rankings
How NIVF compares to all companies
Peer Comparison
NIVF vs similar peers
Compare NIVF with peers
Stack NIVF against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 5 years · 4 quarters